Autres langues Keros Therapeutics, Inc.

Actions

KROS

US4923271013

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 02/10/2026			Varia. 5j.	Varia. 1 janv.
11,36 ^USD	+0,89%		-2,24%	-44,20%

29/09	Keros Therapeutics prévoit un paiement d’étape de 20 millions de dollars de la part de Takeda	MT
29/09	Keros Therapeutics recevra un paiement supplémentaire lié à une étape de développement de la part de son partenaire Takeda	CI

Autres langues

29/09	Keros Therapeutics Expects $20 Million Milestone Payment From Takeda
29/09	Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda
29/09	Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda
28/09	Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
28/09	Keros Therapeutics, Inc. Announces First Patient Dosing In Phase 2 Clinical Trial Evaluating Rinvatercept In DMD
08/09	Keros Therapeutics Approves $5 Million Share Buyback
08/09	Keros Therapeutics, Inc. announces an Equity Buyback for $5 million worth of its shares.
08/09	Keros Therapeutics Announces $5 Million Share Repurchase Authorization
08/09	Keros Therapeutics, Inc. authorizes a Buyback Plan.
03/08	Keros Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
03/08	Keros Therapeutics Reports Second Quarter 2026 Financial Results
30/07	Keros Therapeutics to Receive $20 Million Development Milestone Payment From Takeda
30/07	Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda
30/07	Keros Therapeutics, Inc. Announces to Receive Development Milestone Payment from Partner Takeda Pharmaceutical Company Limited
22/07	Keros Therapeutics, Inc. Announces CFO Changes
22/07	Keros Therapeutics, Inc. Announces Appointment of Annita Tanini as Interim Principal Accounting Officer, Effective August 4, 2026
29/06	Keros Therapeutics, Inc.(NasdaqGM:KROS) added to Russell Microcap Value Benchmark Index
29/06	Keros Therapeutics, Inc.(NasdaqGM:KROS) added to Russell 3000E Index
29/06	Keros Therapeutics, Inc.(NasdaqGM:KROS) added to Russell Microcap Index
29/06	Keros Therapeutics, Inc.(NasdaqGM:KROS) added to Russell 2000 Value-Defensive Index
29/06	Keros Therapeutics, Inc.(NasdaqGM:KROS) added to Russell 2000 Defensive Index
25/06	Keros Therapeutics, Inc. Announces Appointment of Anne Prener as Director, Effective July 1, 2026
25/06	Keros Therapeutics Appoints Anne Prener to its Board of Directors
01/06	Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference
14/05	Keros Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026